Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients

scientific article published on 05 June 2017

Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/AAC.02425-16
P932PMC publication ID5527635
P698PubMed publication ID28584142

P50authorMatthias VoßenQ56389312
Sandra PferschyQ56491010
Daniela KnaflQ88470992
P2093author name stringW Jäger
M Unger
A Maier-Salamon
F Thalhammer
M Haidinger
R Lemmerer
W Lamm
P2860cites workInvasive candidiasis as a cause of sepsis in the critically ill patientQ22305429
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbitsQ34108880
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaQ34505582
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemiaQ34933267
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance NetworkQ35139558
Doripenem Treatment during Continuous Renal Replacement TherapyQ36644597
Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy.Q37036404
Clinical pharmacokinetics of systemically administered antimycotics.Q37239121
Effects of renal replacement therapy on antimicrobial therapy.Q38040475
Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care UnitQ39004033
Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltrationQ39169777
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitroQ39652699
Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilationQ40546653
Invasive candidiasis in intensive care units in China: Risk factors and prognoses of Candida albicans and non-albicans Candida infectionsQ40828130
Optimal prophylactic dosage and disposition of micafungin in living donor liver recipientsQ42163324
Combination antifungal therapy for invasive aspergillosis: a randomized trial.Q44442690
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).Q47643506
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.Q47643534
The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic ShockQ57779776
Pharmacokinetics of Antifungal Agent Micafungin in Critically Ill Patients Receiving Continuous Hemodialysis FiltrationQ59153121
Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltrationQ61777104
Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional StudyQ61833672
Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficientQ83215288
Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational studyQ83485629
Pharmacokinetics/pharmacodynamics of micafungin in a surgical critically ill patient during extracorporeal carbon dioxide removal and continuous renal replacement therapyQ85417874
Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVHQ86441854
Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltrationQ87173846
P433issue8
P407language of work or nameEnglishQ1860
P577publication date2017-06-05
P1433published inAntimicrobial Agents and ChemotherapyQ578004
P1476titleMicafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients
P478volume61

Reverse relations

cites work (P2860)
Q92613683Antifungal Drugs Influence Neutrophil Effector Functions
Q52807819Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.
Q64926124Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy.
Q58079557Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?
Q47876785Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Q91525647Pharmacokinetics of Micafungin in Critically Ill Patients

Search more.